Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Dendritic Cell Sarcoma, Interdigitating 1Burkitt Lymphoma 1

Interventions

Rituximab 55Cyclophosphamide 41Lenalidomide 25Vincristine 23Doxorubicin 22Prednisone 21Etoposide 16ibrutinib 12Gemcitabine 12fludarabine phosphate 10fludarabine 10Peripheral Blood Stem Cell Transplantation 10Carboplatin 10Bendamustine Hydrochloride 10Ifosfamide 9Filgrastim 8polatuzumab vedotin 7obinutuzumab 7Oxaliplatin 7Mycophenolic Acid 7Methotrexate 6Cyclosporine 6venetoclax 5tafasitamab 5Vorinostat 5Radiotherapy 5R-CHOP protocol 5Prednisolone 5Melphalan 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large B-Cell, Diffuse × veltuzumab × Clear all
NCT00596804 2021-08-18

Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma

Gilead Sciences

Phase 1/2 Completed
39 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01101581 2021-08-18

Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL

Gilead Sciences

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡